Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

1P-LSD Also known as:

  • (8β)-N,N-Diethyl-6-methyl-1-propionyl-9,10-didehydroergolin-8-carboxamid[German][ACD/IUPAC Name]
  • (8β)-N,N-Diethyl-6-methyl-1-propionyl-9,10-didehydroergoline-8-carboxamide[ACD/IUPAC Name]
  • (8β)-N,N-Diéthyl-6-méthyl-1-propionyl-9,10-didéhydroergoline-8-carboxamide[French][ACD/IUPAC Name]
  • 1-propionyl-lysergic acid diethylamide
  • 23R2G2G79C
  • Ergoline-8-carboxamide, 9,10-didehydro-N,N-diethyl-6-methyl-1-(1-oxopropyl)-, (8β)-[ACD/Index Name]
  • N,N-diethyl-6-methyl-1-propanoyl-9,10-didehydroergoline-8-carboxamide[ACD/IUPAC Name]
  • UNII:23R2G2G79C

An LSD analogue which appears to be slightly more potent with a shorter duration. Its effects are reported to be extremely similar to LSD, and thus far seems to be similarly safe. Released in late 2014, It has quickly become a highly popular research chemical due to its implicit legality, similarity to LSD and wide availability on the Internet.

Summary

1P-LSD is closely related to LSD and is reported to produce near-identical effects. Little is known about the pharmacology of 1P-LSD, but it likely produces its psychedelic effects by acting on serotonin receptors in the brain. The original synthesis date of 1P-LSD is unknown.

Unlike most research chemicals, 1P-LSD has no prior record in the scientific literature. The first reports of 1P-LSD use surfaced in 2015 following its appearance on the online research chemical market. It was marketed as a legal alternative to LSD alongside other novel lysergamides like ALD-52, ETH-LAD, and AL-LAD.

Subjective effects include geometric visual hallucinations, time distortion, enhanced introspection, conceptual thinking, euphoria, and ego loss. User reports indicate that the subjective effects of 1P-LSD are extremely similar to those of LSD. 1P-LSD is theorized to act as a prodrug for LSD.

This hypothesis is supported by the results of a study, showing 1P-LSD is metabolized to LSD in rats. This predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristic effects include geometric visual hallucinations, time distortion, enhanced introspection, and ego loss.

Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of 1P-LSD. It is presumed to have a similar toxicity and risk profile as LSD, although no evidence currently exists to support this.

It is highly advised to use harm reduction practices if using this substance.

History

A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment.— Donald A. Cooper, Future Synthetic Drugs of Abuse, 1988.

Chemistry

1P-LSD

1P-LSD

It is similar to LSD and is named for the propionyl group bound to the nitrogen of the polycyclic indole group of LSD.

Propionyl consists of the carbonyl chain CH3CH2CO- bound to an amino group. 1P-LSD is homologous to ALD-52, which holds an acetyl group bound to the nitrogen instead of the propionyl group bound at the same location.

The structure of 1P-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group.

At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound.

Common Name1P-LSD
Systematic name1P-LSD
FormulaC_{23}H_{29}N_{3}O_{2}
SMILESCCC(=O)n1cc2c3c1cccc3C4=C[[email protected]](CN([[email protected]@H]4C2)C)C(=O)N(CC)CC
Std. InChiInChI=1S/C23H29N3O2/c1-5-21(27)26-14-15-12-20-18(17-9-8-10-19(26)22(15)17)11-16(13-24(20)4)23(28)25(6-2)7-3/h8-11,14,16,20H,5-7,12-13H2,1-4H3/t16-,20-/m1/s1
Std. InChiKeyJSMQOVGXBIDBIE-OXQOHEQNSA-N
Avg. Mass379.4953 Da
Molecular Weight379.4953
Monoisotopic Mass379.225983 Da
Nominal Mass379
ChemSpider ID52085129

Subscribe for the latest updates

Dose Chart

Oral
Light25-50ug
Common50-125ug
Strong125-200ug

Duration Chart

1P-LSD Duration Data
Onset45-90 minutes
Duration8-12 hours
After-effects6-24 hours

Auditory Effects

Psychological Effects

Pharmacological Effects

Based on its structural similarity to LSD, 1P-LSD likely acts as a partial agonist at the 5-HT2A receptor. The psychedelic effects are thought to primarily come from its efficacy at the 5-HT2A receptors distributed throughout the brain. 1P-LSD also likely displays binding activity at a wide range of monoamine receptors, such as those for dopamine and norepinephrine. However, there is currently no data to support these claims. It has been theorized that 1P-LSD may act as a prodrug for LSD. While 1P-LSD shows only 38% the potency of LSD in mice, LSD is detected via LC-MS when 1P-LSD is incubated in human serum. Follow-up studies are currently being conducted to compare the affinity and selectivity of LSD and 1P-LSD at 5-HT receptors, and to determine whether 1P-LSD is hydrolyzed to LSD in vivo. Otherwise, it is possible that 1P-LSD may be capable of exerting its own psychedelic effect. Prior to the publishing of the above-cited research, medicinal chemist and psychedelic researcher David E. Nichols reportedly commented on the potential 1P-LSD serotonin receptor binding dynamics in private correspondence:

Physical Effects

  • Stimulation - 1P-LSD is usually regarded as very energetic and stimulating without being forced. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocybin which are generally sedating and relaxed.
  • Spontaneous bodily sensations - The "body high" of 1P-LSD can be characterized as proportionally very intense in comparison to its accompanying visual and cognitive effects. It behaves as a euphoric, fast-moving, sharp and location-specific tingling sensation. For some, it is manifested spontaneously at different, unpredictable points throughout the trip, but for most, it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. At moderate to high doses of 1P-LSD, this sensation often approaches its highest level and can become so overwhelming that people may find themselves debilitated with pleasurable sensations.
    • Physical euphoria - It should be noted that this effect is not as reliably induceable as it is with substances like stimulants or entactogens, and can just as easily manifest as extreme physical discomfort without any apparent reason.
  • Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most 1P-LSD experiences. If level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
  • Stamina enhancement - This is generally mild in comparison to the stamina enhancement produced by traditional stimulants.
  • Appetite suppression
  • Bodily control enhancement
  • Difficulty urinating
  • Excessive yawning - This effect is significantly less pronounced than it is with psilocybin and its related compounds, the four-position substituted tryptamines.
  • Nausea - Mild nausea is occasionally reported when consumed in moderate to high dosages and either passes instantly soon after the user has vomited or gradually fades by itself as the peak sets in.
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Muscle contractions
  • Muscle spasms
  • Pupil dilation
  • Increased salivation
  • Vasoconstriction - Vasoconstriction may lead to users feeling cold, especially in the extremities.
  • Seizure - The likelihood is largely extrapolated from the seizures that have been reported from the use of LSD. It is thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as states of dehydration, fatigue, undernourishment or overheating.

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Subjective Effects

Anecdotal reports from many users suggest that the subjective effects of 1P-LSD are so similar to that of LSD so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as psilocybin, LSA and ayahuasca, 1P-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects.

Visual Effects

Enhancements

Distortions

Geometry

The visual geometry of 1P-LSD can be described as more similar in appearance to that of 2C-B or 2C-I than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, synthetic in feel, multicoloured in scheme, flat in shading, sharp in edges, large in size, fast in speed, smooth in motion, angular in its corners, non-immersive in-depth and consistent in intensity.

In the case of higher-level geometry, this substance is level 8A dominant but is also capable of inducing 8B Geometry under the right circumstances.

Hallucinatory states

1P-LSD is capable of producing a full range of hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics, specifically tryptamines like DMT or psilocybin mushrooms. These effects include:

Legal Status

1P-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: 1P-LSD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.
  • Canada: 1P-LSD is controlled as Schedule III substance under the Precursor Control Regulations of the Controlled Drugs and Substances Act.
  • Denmark: As of August 25, 2015, 1P-LSD is specifically named on the list of illegal substances.
  • Germany: 1P-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Latvia: 1P-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
  • Lithuania: 1P-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since September 21, 2015.
  • Sweden: Following its sale as a designer drug, 1P-LSD was made illegal in Sweden on January 26, 2016.
  • Switzerland: 1P-LSD is illegal in Switzerland as of December 2015.
  • Turkey: 1P-LSD is illegal in Turkey as of February 2016.
  • United Kingdom: 1P-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
  • United States: Since 1P-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.
  • Sources

    References

    1. "1P-LSD (Google Trends)". Retrieved January 1, 2020.
    2. Wagmann, Lea; Richter, Lilian H. J.; Kehl, Tobias; Wack, Franziska; Pettersson Bergstrand, Madeleine; Brandt, Simon D.; Stratford, Alexander; Maurer, Hans H.; Meyer, Markus R. (2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. :10.1007/s00216-018-1558-9.  1618-2642.
    3. Brandt, S. D.; Kavanagh, P. V.; Westphal, F.; Stratford, A.; Elliott, S. P.; Hoang, K.; Wallach, J.; Halberstadt, A. L. (2015). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)". Drug Testing and Analysis. 8 (9): 891–902. :10.1002/dta.1884.  1942-7603.
    4. Cooper, Donald A. (1988). "Future Synthetic Drugs of Abuse". Proceedings of the international symposium on the forensic aspects of controlled substances. p. 79.  978-0-93211-509-6.
    5. "Kman1898" (January 13, 2015). "The Big & Dandy 1P-LSD Thread, Volume 1". Bluelight.org. Retrieved January 1, 2020.
    6. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. :10.1002/nrc.20023.  1520-6769.
    7. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. :10.1016/0014-2999(94)90669-6.  0014-2999.
    8. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. :10.1016/j.neuro.2007.04.005.  0161-813X. PMID 17572501.
    9. Nichols, David E. (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–181. :10.1016/j.pharmthera.2003.11.002.  0163-7258.
    10. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    11. "Synthetische Drogen: Neues Gesetz soll "Legal Highs" bekämpfen" [Synthetic drugs: New law is to combat legal highs] (in German). Der Standard. September 28, 2011. Retrieved January 1, 2020.
    12. "Entwurf: Bundesgesetz, mit dem ein Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird" (PDF) (in German). Retrieved January 1, 2020.
    13. "Precursor Control Regulations (SOR/2002-359) - SCHEDULE". Government of Canada. Retrieved January 1, 2020.
    14. "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
    15. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    16. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
    17. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    18. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    19. "LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo" (in Lithuanian). Retrieved January 1, 2020.
    20. "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
    21. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
    22. "Karar Sayısı : 2016/8548" (PDF) (in Turkish). Resmi Gazete. Retrieved January 15, 2020.
    23. "Psychoactive Substances Act 2016". UK Government. Retrieved January 1, 2020.
    24. "Introduction to the Federal Controlled Substance Analogue Act". Erowid. January 2001. Retrieved January 1, 2020.

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.